Platelet ADP receptor antagonists: Ticlopidine and clopidogrel

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 1, 2004, Pages 55-64

  Jacobson, Alan K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiplatelet; Atherothrombosis; Clopidogrel; Thienopyridine; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CIMETIDINE; CLOPIDOGREL; DIGOXIN; FIBRINOGEN RECEPTOR ANTAGONIST; THEOPHYLLINE; THROMBOCYTE RECEPTOR; TICLOPIDINE; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD TOXICITY; CEREBRAL ARTERY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; STANDARD; STROKE; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 2942641718     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.03.002     Document Type: Review

References (76)

1. Drouet L. Atherothrombosis as a systemic disease. Cerebrovascular Disease 2002; 13(supplement 1): 1-6.
2. Guilmot J, Diot E & Gruel Y. Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis. Presse Medicale 2000; 29: 709-716.
3. Rauch U, Osende J, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Annals of Internal Medicine 2001; 134: 224-238.
4. Fitzgerald D. Vascular biology of thrombosis: the role of platelet-vessel wall adhesion. Neurology 2001; 57(supplement 2): S1-S4.
5. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000; 101: E76-E80.
6. Hoylaerts M, Oury C, Toth-Zsamboki E & Vermylen J. ADP receptors in platelet activation and aggregation. Platelets 2000; 11: 307-309.
7. Puri R & Colman R. ADP-induced platelet activation. Critical Reviews in Biochemistry and Molecular Biology 1997; 32: 437-502.
8. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy. 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists Collaboration. British Medical Journal 1994; 308(6921): 81-106.
9. Hirsh J, Dalen J, Fuster V, et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995; 108: 247S-257S.
10. Cappelleri J, Lau J, Kupelnick B & Chalmers T. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. Online Journal of Current Clinical Trials 1995; . Doc No 174.
11. Hirschowitz B & Hawkey C. Questions regarding future research on aspirin and the gastrointestinal tract. The American Journal of Medicine 2001; 110: 74S-78S.
12. Howard P. Aspirin resistance. The Annals of Pharmacotherapy 2002; 36: 1620-1624.
13. Gum P, Kottke-Marchant K, Welsh P, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology 2003; 41: 961-965.
14. Gent M. The CAPRIE trial: culmination of the preregistration program for clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Clopidogrel versus aspirin in patients at risk of ischaemic events. Seminar in Thrombosis and Hemostasis 1999; 25(supplement 2): 1-2.
15. Haynes R, Sandler R, Larson E, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Archives of Internal Medicine 1992; 152: 1376-1380.
16. Quinn M & Fitzgerald D. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-1672.
17. Shah J, Fratis A, Ellis D, et al. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. Journal of Clinical Pharmacology 1990; 30: 733-736.
18. Di Minno G, Cerbone A, Mattioli P, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. The Journal of Clinical Investigation 1985; 75: 328-338.
19. Storey F. The P2Y 12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001; 12: 197-209.
20. Heptinstall S, May J. & Glenn J. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thrombosis Haemostasis 1995; 74: 1310-1315.
21. Puri R & Colman R. ADP-induced platelet activation. Critical Reviews in Biochemical and Molecular Biology 1997; 32: 437-502.
22. Desager J. Clinical pharmacokinetics of ticlopidine. Clinical Pharmacokinetics 1994; 26: 347-355.
23. Knudsen J, Bastain W, Sefton C, et al. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992; 22: 579-589.
24. Lubbe D & Berger P. The thienopyridines. Journal of Interventional and Cardiology 2002; 15: 85-93.
25. Prescribing Information: Ticlid (ticlopidine hydrochloride) Tablets. Physicians Desk Reference. Montvale, NJ: Medical Economics Co., 2004..
26. Hass W, Easton J, Adams H, et al. randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. The New England Journal of Medicine 1989; 321: 501-507.
27. McTavish D, Faulds D & Goa K. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-259.
28. Gent M, Blakely J, Easton J, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke 1988; 19: 1203-1210.
29. Hass W, Easton J, Adams H, et a]. randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. The New England Journal of Medicine 1989; 321: 501-507.
30. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82: 17-26.
31. Scrutinio D, Cimminiello C, Marubini E, et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. Journal of American College of Cardiology 2001; 37: 1259-1265.
32. Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. The Journal of Laboratory and Clinical Medicine 1989; 114: 84-91.
33. Limet R, David J, Magotteaux P, et al. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. The Journal of Thoracic Cardiovascular Surgery 1987; 94: 773-783.
34. Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. The New England Journal of Medicine 1998; 339: 1665-1671.
35. Hass W, Easton J, Adams H, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. The New England Journal of Medicine 1989; 321: 501-507.
36. Gent M, Blakely J, Easton J, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
37. Lincoff A, Popma J, Ellis S, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. Journal of American College of Cardiology 1992; 19: 926-935.
38. Tan K, Sulke N, Taub N & Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. Journal of American College of Cardiology 1995; 25: 855-865.
39. Serruys P, de JP, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England Journal of Medicine 1994; 331: 489-495.
40. Schomig A, Neumann F, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. The New England Journal of Medicine 1996; 334: 1084-1089.
41. Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. The New England Journal of Medicine 1998; 339: 1665-1671.
42. Bertrand M, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (Fantastic) study. Circulation 1998; 98: 1597-1603.
43. Easton J. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Seminars in Thrombosis Hemostasis 1999; 25(supplement 2): 77-82.
44. Pierce C, Houle J, Dickinson J, et al. Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. Seminars in Thrombosis Hemostasis:35-9..
45. Sharis P, Cannon C & Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Annals of Internal Medicine 1998; 129: 394-405.
46. Caplain H, Donat F, Gaud C & Necciari J. Pharmacokinetics of clopidogrel. Seminars in Thrombosis Hemostasis 1999; 25(supplement 2): 25-28.
47. Gurbel P, Cummings C, Bell C, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. American Heart Journal 2003; 145: 239-247.
48. Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheterization and Cardiovascualr Intervention 2002; 55: 436-441.
49. Besson G & Bogousslawsky J. Current and future options for the prevention and treatment of stroke. CNS Drugs 1995; 3: 351-362.
50. Schror K. Antiplatelet drugs: a comparative review. Drugs 1995; 50: 7-28.
51. Bennett CL, Connors JM & Moake JL. Clopidogrel and thrombotic thrombocytopenic purpura. The New England Journal of Medicine 2000; 343: 1193-1194.
52. Peters R, Mehta S, Fox K, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-1687.
53. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
54. Mehta S & Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal 2000; 21: 2033-2041.
55. Yusuf S, Zhao F, Mehta S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine 2001; 345: 494-502.
56. Taniuchi M, Kurz HI & Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104: 539-543.
57. Bertrand ME, Rupprecht HJ & Urban P. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
58. Muller C, Buttner HJ & Petersen J. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590-593.
59. Mehta S, Yusuf S, et al. Peters R.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
60. Steinhubl S, Berger P, Mann J, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial 2002;288:2411-20..
61. Waksman R, Bhargava B, White R, et al. Intracoronary radiation for patients with refractory in-stent restenosis: an analysis from the WRIST-Crossover Trial. Washington Radiation for In-stent Restenosis Trial. Cardiovascular Radiation Medicine 1999; 1: 317-322.
62. Waksman R, Ajani A, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106: 776-778.
63. Blanchard J, Carreras L & Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1994; 35: 523-528.
64. Bergqvist D, Almgren B & Dickinson J. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results form the Swedish Ticlopidne Multicentre Study (STIMS). European Journal of Vascular and Endovascular Surgery 1995; 10: 69-76.
65. Lindblad B, Wakefield T, Stanely T, et al. Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey. European Journal of Vascular and Endovascular Surgery 9:267-71.
66. Castelli P, Basellini A, et al. Agus G.Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. International Surgery 1986; 71: 252-255.
67. Hankey G, Sudlow C, Dunbabin D. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. In Cochrane Database Syst Rev 2000, p. CD001246.
68. Regensteiner J & Hiatt W. Current medical therapies for patients with peripheral arterial disease: a critical review. The American Journal of Medicine 2002; 112: 49-57.
69. Hiatt W. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. Journal of International Medicine 2002; 251: 193-206.
70. Albers G & Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2001; 32: 2948-2949.
71. Albers G. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology 2000; 54: 1022-1028.
72. Hacke W. From CURE to Match: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovascular Disease 2002; 13(supplement 1): 22-26.
73. Khot U & Nissen S. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. Journal of American College of Cardiology 2002; 40: 218-219.
74. Gorelick P, Born G, D'Agostino R, et al. Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 1999; 30: 1716-1721.
75. Gaspoz J, Coxson R, Goldman R et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. The New England Journal of Medicine 2002; 346: 1800-1806.
76. Sarasin F, Gaspoz J & Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Archives of Internal Medicine 2000; 160: 2773-2778.